Skip to main content
Back
Watch Compare

Anika Therapeutics, Inc.

Data quality: 100%
ANIK
Nasdaq Manufacturing Measuring & Analyzing Instruments
$14.76
▼ $0.46 (-3.02%)
Mkt Cap: 220.07 M
Price
$15.26
Mkt Cap
220.07 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -6.53% annually over 5 years
Generating 4.36 M in free cash flow
Capital efficient — spends only 6.05% of revenue on capex

Growth

Revenue Growth (5Y)
-6.53%
Below sector avg (1.82%)
Revenue (1Y)-5.91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-7.39%
Above sector avg (-53.41%)
ROIC-5.11%
Net Margin-9.64%
Op. Margin-9.80%

Safety

Debt / Equity
N/A
Current Ratio5.32
Interest CoverageN/A

Valuation

PE (TTM)
-20.23
Below sector avg (-1.48)
P/B Ratio1.50
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -20.2 -1.5
P/B 1.5 1.6
ROE % -7.4 -53.4
Net Margin % -9.6 -41.5
Rev Growth 5Y % -6.5 1.8
D/E — 0.3

ETFs Holding This Stock

SQLV logo SQLV Royce Quant Small-Cap Quality Value ETF
0.21% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0.03% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.02% weight
GSCYX GSCYX
0.01% weight
GSCZX GSCZX
0.01% weight
EES logo EES WisdomTree U.S. SmallCap Fund
0.01% weight
AVSCX AVSCX
0.01% weight
VVICX VVICX
0.00% weight
IRSIX IRSIX
0.00% weight
IRCIX IRCIX
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -5.91% Revenue Growth (3Y) -17.72%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -6.53% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 112.82 M Net Income (TTM) -10.88 M
ROE -7.39% ROA -5.77%
Gross Margin 56.56% Operating Margin -9.80%
Net Margin -9.64% Free Cash Flow (TTM) 4.36 M
ROIC -5.11% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.32
Interest Coverage N/A Asset Turnover 0.60
Working Capital 82.50 M Tangible Book Value 137.10 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -20.23 Forward P/E N/A
P/B Ratio 1.50 P/S Ratio 1.95
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 1.98%
Market Cap 220.07 M Enterprise Value 162.08 M
Per Share
EPS (Diluted TTM) -0.76 Revenue / Share 7.82
FCF / Share 0.30 OCF / Share 0.78
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 6.05% FCF Conversion -40.09%
SBC-Adj. FCF -6.66 M Growth Momentum 0.62

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 112.82 M 119.91 M 166.66 M 156.24 M 147.79 M
Net Income -10.88 M -56.39 M -82.67 M -14.86 M 4.13 M
EPS (Diluted) -0.76 -3.83 -5.64 -1.02 0.28
Gross Profit 63.81 M 76.00 M 103.09 M 93.58 M 82.94 M
Operating Income -11.05 M -5.10 M -87.64 M -19.40 M 2.62 M
EBITDA — — — — —
R&D Expenses 25.77 M 25.54 M 32.69 M 28.18 M 27.33 M
SG&A Expenses 49.09 M 55.56 M 95.85 M 84.79 M 74.10 M
D&A 5.37 M 6.88 M 6.43 M 6.70 M 6.48 M
Interest Expense — — — — —
Income Tax 672,000.0 6.06 M -2.66 M -3.89 M -1.71 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 190.27 M 202.74 M 270.63 M 349.13 M 347.54 M
Total Liabilities — — — — —
Shareholders' Equity 143.47 M 153.99 M 212.27 M 285.56 M 287.09 M
Total Debt — — — — —
Cash & Equivalents 57.48 M 55.63 M 72.87 M 86.33 M 94.39 M
Current Assets 103.36 M 113.65 M 163.31 M 169.55 M 168.53 M
Current Liabilities 21.91 M 23.31 M 31.06 M 27.91 M 29.80 M